Economic evaluation of percutaneous left atrial appendage occlusion, dabigatran, and warfarin for stroke prevention in patients with nonvalvular atrial fibrillation

Circulation

Volumn 127, Issue 24, 2013, Pages 2414-2423

  Singh, Sheldon M ^a,b   Micieli, Andrew ^f   Wijeysundera, Harindra C ^a,b,c,d,e  

^a Schulich Heart Centre   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^f UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Anticoagulants; Atrial appendage; Atrial fibrillation; Bleeding; Prevention

Indexed keywords

DABIGATRAN; WARFARIN;

AGED; ALCOHOL CONSUMPTION; ANTICOAGULANT THERAPY; ARTICLE; ARTIFICIAL EMBOLISM; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CANADA; CEREBROVASCULAR ACCIDENT; COMORBIDITY; CORONARY ARTERY BYPASS GRAFT; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; CREATININE CLEARANCE; DIABETES MELLITUS; DISEASE SEVERITY; FEMALE; HEART ATRIUM APPENDAGE; HEART ATRIUM FIBRILLATION; HEART CATHETERIZATION; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; KIDNEY DISEASE; KIDNEY FUNCTION; LEFT ATRIAL APPENDAGE CLOSURE DEVICE; LIFE EXPECTANCY; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS LEFT ATRIAL APPENDAGE OCCLUSION; PERICARDIAL EFFUSION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSIENT ISCHEMIC ATTACK;

ANTICOAGULANTS; ATRIAL APPENDAGE; ATRIAL FIBRILLATION; BLEEDING; PREVENTION;

AGED; ATRIAL APPENDAGE; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; COMPUTER SIMULATION; CORONARY OCCLUSION; COST-BENEFIT ANALYSIS; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MARKOV CHAINS; MODELS, STATISTICAL; ONTARIO; PERCUTANEOUS CORONARY INTERVENTION; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; STROKE; WARFARIN;

EID: 84879303265     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.112.000920     Document Type: Article

References (45)

1. Roger VL, Go AS, Lloyd-Jones DM, Benjamin E.J., Berry HD, Borden WB, Bravata DM, Dai S, Ford E.S., Fox CS, Fullerton HJ, Gillespie C, Halpern S.M., Heit JA, Howard VJ, Kissela BM, Kittner S.J., Lackland DT, Lichtman JH, Lisabeth LD, Makuc D.M., Marcus GM, Marelli A, Matchar DB, Moy C.S., Mozaffarian D., Mussolino ME, Nichol G, Paynter NP, Soliman EZ, Sorlie PD, Sotoodehnia N, Turan TN, Virani SS, Wong ND, Woo D, Turner MB; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation. 2011;123:e18-e209.
2. Hart RG, Pearce LA, Aguilar MI Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857-867.
3. Baczek VL, Chen WT, Kluger J, Coleman CI Predictors of warfarin use in atrial fibrillation in the United States: a systematic review and meta-analysis. BMC Fam Pract. 2012;13:5.
4. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J., Oldgren J, Parekh A, Pogue J., Reilly PA, Themeles E, Varrone J, Wang S., Alings M, Xavier D, Zhu J., Diaz R, Lewis BS, Darius H, Diener H.C., Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.
5. Product monograph: Pradax. Revised January 27, 2012. Burlington, Canada: Boehringer Ingelheim Canada Ltd; 2012.
6. Skanes AC, Healey JS, Cairns J.A., Dorian P., Gillis AM, McMurtry MS, Mitchell LB, Verma A, Natell S. Focused 2012 update on the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol. 2012;28:125-136.
7. Holmes DR, Reddy VY, Turi Z.G., Doshi SK, Sievert H, Buchbinder M, Mullin C.M., Sick P. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomized non-inferiority trial. Lancet. 2009;374:534-542.
8. Guidelines for the Economic Evaluation of Health Technologies: Canada. 3rd ed. Ottawa, Canada: Canadian Agency for Drugs and Technologies in Health; 2006.
9. Gallego P, Roldán V, Torregrosa J.M., Gálvez J, Valdés M, Vicente V., Marín F, Lip GY Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation. Circ Arrhythm Electrophysiol. 2012;5:312-318.
10. Tsadok MA, Jackevicius CA, Essebag V, Eisenberg M.J., Rahme E., Humphries KH, Tu JV, Behlouli H, Pilote L. Rhythm versus rate control therapy and subsequent stroke or transient ischemic attack in patients with atrial fibrillation. Circulation. 2012;126:2680-2687.
11. Hux JE, Booth GL, Slaughter P.M., Laupacis A., eds. Diabetes in Ontario: An ICES Practice Atlas. Ontario, Canada: Institute for Clinical Evaluative Sciences; 2003.
12. Tu K, Chen Z, Lipscombe LL Prevalence and incidence of hypertension from 1995 to 2005: a population based study. CMAJ. 2008;178:1429-1435.
13. Gottdiener JS, Arnold AM, Aurigemma G.P., Polak JF, Tracy RP, Kitzman DW, Gardin J.M., Rutledge JE, Boineau RC Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol. 2000;35:1628-1637.
14. De Caterina R., Connolly SJ, Pogue J, Chrolavicius S., Budaj A, Morais J, Renda G., Yusuf S. Mortality and predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W. Eur Heart J. 2010;31:2133-2140.
15. Fogelholm R, Murros K, Rissanen A., Avikainen S. Long term survival after primary intracerebral haemorrhage: a retrospective population based study. J Neurol Neurosurg Psychiatry. 2005;76:1534-1538.
16. The Clopidogrel in Unstable Angina to Prevent recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502.
17. McNamara RL, Tamariz LJ, Segal J.B., Bass EB Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography. Ann Intern Med. 2003;139:1018-1033.
18. Freeman JV, Zhu RP, Owens D.K., Garber AM, Hutton DW, Go AS, Wang P.J., Turakhia M P. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med. 2011;154:1-11.
19. Corsico CD. Dabigatran (NDA-22-512). Cardio-Renal Advisory Committee Meeting, September 20, 2010. http://www.fda.gov/downloads/Advisory-Committees/ CommitteesMeetingMaterials/Drugs/CardiovascularandRenal-DrugsAdvisoryCommittee/ UCM226706.pdf. Accessed May 7, 2013.
20. Aguilar MI, Hart R, Pearce LA Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2007;(3):CD006186.
21. Larsen TB, Lip GY, Skjøth F, Due K.M., Overvad K., Hvilsted Rasmussen L. Added predictive ability of the CHA2DS2VASc risk score for stroke and death in patients with atrial fibrillation: the prospective Danish Diet, Cancer, and Health cohort study. Circ Cardiovasc Qual Outcomes. 2012;5:335-342.
22. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Guidelines for the management of atrial fibrillation. Europace. 2010;12:1360-1420.
23. O'Brien C.L., Gage BF Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. JAMA. 2005;293:699-706.
24. Shah SV, Gage BF Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation. 2011;123:2562-2570.
25. Lip G.Y., Frison L, Halperin J.L., Lane DA Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/ Alcohol Concomitantly) score. J Am Coll Cardiol. 2011;57:173-180.
26. Apostolakis S, Lane DA, Guo Y, Buller H., Lip GYH. Performance of the HEMORR2HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation. J Am Coll Cardiol. 2012;60:861-867.
27. Fang MC, Go AS, Chang Y, Hylek E.M., Henault LE, Jensvold NG, Singer DE Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med. 2007;120:700-705.
28. Vaccaro O, Eberly LE, Neaton J.D., Yang L., Ricchardi G, Stamler J. Impact of diabetes and previous myocardial infarction on long-term survival: 25 year mortality follow-up of primary screenees of the Multiple Risk Factor Intervention Trial. Arch Intern Med. 2004;164:1438-1443.
29. Fang MC, Go AS, Chang Y, Borowsky L.H., Pomernacki NK, Udaltsova N, Singer DE Warfarin discontinuation after starting warfarin for atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2010;3:624-631.
30. Eckman MH, Rosand J, Knudsen K.A., Singer DE, Greenberg SM Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis. Stroke. 2003;34:1710-1716.
31. Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care. 2000;38:583-637.
32. Thomson R, Parkin D, Eccles M., Sudlow M, Robinson A. Decision analysis and guidelines for anticoagulant therapy to prevent stroke in patients with atrial fibrillation. Lancet. 2000;355:956-962.
33. Drugs funded by Ontario Drug Benefit (ODB) Program: E-Formulary. Ontario Ministry of Health and Long-Term Care Web site. http://www.health.gov.on.ca/ english/providers/program/drugs/odbf-eformulary.html. Accessed August 17, 2012.
34. Schulman S, Anderson DR, Bungard T.J., Jaeger T., Kahn SR, Wells P, Wilson SJ Direct and indirect costs of management of long-term warfarin therapy in Canada. J Thromb Haemost. 2010;8:2192-2200.
35. Ontario Case Costing Initiative. http://www.occp.com/mainPage.htm. Accessed September 30, 2012.
36. Schedule of benefits for physician services under the Health Insurance Act. Ministry of Health and Long Term Care Web site. http://www.health.gov.on. ca/english/providers/program/ohip/sob/physserv/physserv-mn.html. Accessed September 30, 2012.
37. Gage BF, Cardinalli AB, Owens DK The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med. 1996;156:1829-1836.
38. Garg P, Cohen DJ, Gaziano T, Mauri L. Balancing the risks of restenosis and stent thrombosis in bare-metal versus drug-eluting stents: results of a decision analytic model. J Am Coll Cardiol. 2008;51:1844-1853.
39. Connolly SJ, Eikelboom J, O'Donnell M, Pogue J, Yusuf S. Challenges of establishing new antithrombotic therapies in atrial fibrillation. Circulation. 2007;116:449-455.
40. Huynh T, Théroux P, Bogaty P., Nasmith J, Solymoss S. Aspirin, warfarin, or the combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery. Circulation. 2001;103:3069-3074.
41. Homma S, Thompson JL, Pullicino P.M., Levin B., Freudenberger RS, Teerlink JR, Ammon SE, Graham S, Sacco R.L., Mann DL, Mohr JP, Massie BM, Labovitz A.J., Anker SD, Lok DJ, Ponikowski P, Estol C.J., Lip GY, Di Tullio MR, Sanford AR, Mejia V, Gabriel AP, del Valle ML, Buchsbaum R; WARCEF Investigators. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med. 2012;366:1859-1869.
42. Munkholm-Larsen S., Cao C, Yan T.D., Pehrson S., Dixen U. Percutaneous atrial appendage occlusion for stroke prevention in patients with atrial fibrillation: a systematic review. Heart. 2012;98:900-907.
43. Agarwal S, Hachamovitch R, Menon V. Current trial associated outcomes with warfarin in prevention of stroke in patients with non-valvular atrial fibrillation: a meta-analysis. Arch Intern Med. 2012;172:623-631.
44. Reddy VY, Holmes D, Doshi S.K., Neuzil P., Kar S. Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry. Circulation. 2011;123:417-424.
45. Sorensen SV, Kansal AR, Connolly S, Peng S., Linnehan J, Bradley-Kennedy C, Plumb JM Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Thromb Haemost. 2011;105:908-919.